Real-world data covering 376 patients treated with Janus kinase inhibitors for atopic dermatitis and alopecia areata reveals reassuring safety profiles without major cardiovascular or malignancy signals, though clinicians must remain vigilant for metabolic changes and sex-specific adverse events.
Medications such as abrocitinib, baricitinib, upadacitinib, and ritlecitinib target dysregulated cytokine signaling pathways.
A single-center retrospective observational study evaluated electronic medical record data from December 2020 to June 2025 to track adult patients diagnosed with atopic dermatitis or alopecia areata who received treatment with dermatologic JAK inhibitors. The research encompassed 376 patients monitored under routine clinical practice conditions rather than the strict environment of randomized controlled trials.
Retrospective Findings in 376 Patients Treated With JAK Inhibitors
The investigation confirmed the absence of major safety signals regarding major adverse cardiovascular events or malignancies. Malignancies identified during the evaluation included one stage IA melanoma in a patient taking abrocitinib at 100 mg, one mantle cell lymphoma under upadacitinib at 15 mg, and two cases linked to baricitinib at 4 mg consisting of ductal breast carcinoma and a grade 1 pancreatic neuroendocrine tumor. Three fully excised basal cell carcinomas occurred across patients taking upadacitinib, baricitinib, and abrocitinib, alongside a single instance of Pneumocystis jirovecii pneumonia under upadacitinib at 30 mg that required hospitalization and resolved with full recovery.
Epidemiology data presented at a recent symposium provided additional perspective on safety concerns surrounding these therapies. Experts evaluated biomarker data showing that JAK inhibitors lower high-sensitivity C-reactive protein and modulate cardiovascular risk factors. One evaluated study indicated that upadacitinib might improve myocardial function, a development described as hypothesis-generating and requiring further investigation.
Cardiovascular Risk Profiles and Expert Evaluation at Fall Clinical
Presenters shared real-world cases featuring patients with complex comorbidities including cancer, cardiovascular disease, and histories of clotting. Clinical experts emphasized that seven-year safety outcomes for these medications in atopic dermatitis compare favorably with other established treatments. Attendees heard that seven-year safety rates of those drugs in atopic dermatitis are no higher than the rates of apremilast in psoriasis or psoriatic arthritis
according to symposium presentations.
Physicians Must Maintain Vigilance over Sex-Specific Adverse Events
The retrospective cohort study was notified to the Italian Medicines Agency under study code JAKiSafe, with approval from the competent ethics committee under the Declaration of Helsinki. By capturing early or low-grade clinical and laboratory abnormalities, researchers documented emerging sex-specific adverse events, including menstrual disturbances.
Specialists warn that positive epidemiological findings do not lessen the need for careful oversight. Reassuring safety metrics require continuous vigilance from attending physicians managing heterogeneous patient populations. In the words of clinical presenters addressing attendees, that seven-year data is very reassuring, but it doesn’t mean that we don’t need to monitor patients.